Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 9/20 | 0.36 |
| ▸ | ACE | P12821 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.34 |
| ▸ | HSP90B1 | P14625 | 3/20 | 0.34 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20203495 | 0.79 | ACE (0.40) | HSP90AA1ACEHSP90B1 | |
| SCHEMBL18806180 | 0.78 | CDK1 (0.44) | HSP90AA1KCNH2HSP90B1GPBAR1KDM4E | |
| SCHEMBL18819907 | 0.75 | HSP90AA1 (0.38) | HSP90AA1HSP90B1 | |
| SCHEMBL20203602 | 0.72 | CDK1 (0.41) | HSP90AA1KDM4EALDH1A1KMT2A | |
| SCHEMBL20203582 | 0.71 | KDR (0.40) | HSP90AA1KDM4EALDH1A1 | |
| SCHEMBL23733468 | 0.71 | NPC1 (0.42) | HSP90AA1KDM4EALDH1A1 | |
| SCHEMBL20203643 | 0.71 | HSP90AA1 (0.40) | HSP90AA1KCNH2HSP90B1 | |
| SCHEMBL20203586 | 0.71 | ALDH1A1 (0.37) | HSP90AA1HSP90B1KDM4EALDH1A1KMT2A | |
| SCHEMBL20203456 | 0.71 | GRM5 (0.41) | HSP90AA1KCNH2ALDH1A1TP53KMT2A | |
| SCHEMBL23733491 | 0.70 | CYP2C19 (0.38) | HSP90AA1KCNH2HSP90B1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | TEIJIN PHARMA LIMITED (JP) | 2021-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | CDK4, CDK6, CDK16 | HSP90AA1 4289/4885ACE 404/4885KCNH2 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.